Peripheral blood stem cell transplantation (PBSCT) is an indispensable treatment option for progressive malignant diseases. Autologous PBSCT (auto-PBSCT) is usually performed on patients with malignant disease without residual malignant cells in bone marrow. Allogeneic PBSCT (allo-PBSCT) is usually performed on patients with progressive hematological malignancies. In 2022, a total of 976 related and 310 unrelated allo-PBSCT procedures were performed in Japan.
